Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
Jennifer Miles, PharmD, and Yahsin White, PharmD
Wellmont Cancer Institute—Johnson City, Johnson City, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Jennifer Miles, PharmD, 378 Marketplace Blvd, Suite 10, Johnson City, TN 37604. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2018;9(7):750–754 |
© 2018 Harborside™
The treatment of breast cancer has been revolutionized by the development of HER2-targeted treatments for patients who are HER2 positive. The HER2 protein is present at high levels in about 30% of breast cancer patients. These high levels are associated with a greater chance of metastasis, relapse, and decreased survival. The current standard of care for early-stage HER2-positive patients includes treatment with 1 year of trastuzumab therapy. Although trastuzumab has improved outcomes, there is still a 20% chance for tumor recurrence and a 16% chance of death. Neratinib was developed to give patients with early-stage HER2-positive breast cancer an option to increase the disease-free survival rate. The 5-year invasive disease-free survival rate was 90.2% (95% confidence interval = 88.3–91.8) in the neratinib group and 87.7% (95% confidence interval = 85.7–89.4) in the placebo group.
For access to the full length article, please sign in